All News
Remission Unlikely in RA
Dr. Marwan Bukhari (editor of Rheumatology) has written an editorial wherein he suggests that true remission is hard to achieve. He notes that "remission as a target is a noble objective that we should all aspire to but we should not chastise our practice if we do not achieve it, as more and more evidence suggests that we should consider it the ideal but not the norm."
Read ArticleRheumNow Podcast - MTX vs. Etanercept in Psoriatic Arthritis (2.15.19)
Dr. Jack Cush discusses the news from the past week on RheumNow.com - including the SEAM trial, MRI guided T2T, biologics and infection, contraceptive use, ANA negative lupus, etc.
Read ArticleSEAM-PsA Study - Does Monotherapy MTX Win Despite Losing to Etanercept in Psoriatic Arthritis?
The SEAM-PsA study examined the efficacy of methotrexate monotherapy, etanercept monotherapy or the combination of MTX and ETN in psoriatic arthritis patients, and found that ETN monotherapy was equivalent to combination therapy - and that both were superior to MTX alone in clinical (ACR and MDA) and radiographic responses.
Read ArticleRheumNow Podcast – Downside of Lupus (2.9.19)
Dr. Jack Cush reviews this past week's news and reports from RheumNow.com:
Read ArticleBiologic High Out of Pocket Costs for Medicare Patients
Specialty tier drugs, including biologics, accounts for nearly half of all medication spending by Medicare Part D patients. High out-of-pocket costs for these patients is a major concern.
Read ArticleRheumNow Podcast – TNFs and the Inflammasome (1.25.19)
Dr Jack Cush reviews the news from the past week at RheumNow.com.
Read ArticleDoes Seropositivity Change with Therapy?
A subanalysis of the early rheumatoid arthritis (RA) "IMPROVED" study has shown that changes in RA-autoantibody levels are not associated with disease activity or or long-term drug response, but instead reflect intensity of immunosuppression.
Read Article2018 Rheumatology Year In Review
This annual appraisal of hallmark moments, news and research articles from 2018 are gleaned from that published in RheumNow during the last year and filtered by other news sources and literature review. The top 10 list herein is rooted in what rheumatologists should know and what will likel
Read ArticleRheumNow Podcast – Can RA Be Prevented (12.7.18)
Dr. Jack Cush reviews the news and new journal articles from the past week on RheumNow.com:
Read ArticleThe RheumNow Podcast – Heartbreak of Methotrexate (11.16.18)
Dr. Jack Cush reviews the news from the past week at RheumNow.com.
Read ArticleRheumNow Weekly Podcast – 3 Wiseguy Rheumatologists (11.9.18)
Dr Jack Cush reviews the News and Journal reports from the past week on RheumNow.com. Be sure to check out our upcoming meeting in March 2019 - RheumNow Live.
Read ArticleRheumNow ACR Week in Review: ACR Wrap-Up (10.26.18)
This past week in Chicago gave us a plethora of new and eye-opening research, people, KOLs, exhibits, sessions, guidelines, posters and a never-ending supply of coffee served in small paper cups. ACR 2018 highlights for me included:
Read ArticleACR 2018 - Day 4 Report
Highlights from Tuesday and Wednesday (days 3 and 4) from the ACR annual meeting include: the important and impactful abstracts covered by the Rheumatology Roundup session; upadacitinib clinical trials; and the baricitinib CV and VTE safety analysis.
Read ArticleACR 2018 - Day 2 Report
Monday was a packed day of sessions and studies. Here are our just a few of our highlights.
Read ArticleACR 2018 - Day 1 Report
RheumNow is in Chicago covering the ACR annual meeting. Here are the highlights from Sunday (day one). Be sure to check our complete coverage, including articles, video reports and tweets, at acr18.rheumnow.com.
Read ArticleRheumNow Week in Review – Vitamin D Falls Again (10.4.18)
Dr. Jack Cush reviews the news from the past week on RheumNow.com.
Read ArticlePredictive Risk Factors for Uveitis in JIA
Researchers from Germany have studied a large cohort of juvenile idiopathic arthritis (JIA) patients and shown that JIA disease activity scores and laboratory biomarkers could be used to better define the group of JIA patients at high risk of uveitis onset.
Read ArticleElder Rheumatoids Less Likely to Receive Biologics
Multiple studies have shown that elderly rheumatoid arthritis (RA) patients tend to be under-treated and receive DMARD therapies less often than younger RA patients.
Read ArticleRheumNow Week in Review – I Wanna New Drug (9.28.18)
Dr. Jack Cush reviews the news from the past week on RheumNow.com, including news on inappropriate opioids, pre-clinical RA treatment, DMARDs in Gout, the decline of arthroscopy, and a pain in the mouth.
Read ArticleVenous Thromboembolism Increased with Rheumatoid Arthritis, Not with TNF Inhibition
Venous thromboembolism (VTE) is a common adverse event throughout medicine and includes both pulmonary embolism (PE) and deep vein thrombosis (DVT). The cost of diagnosing a thromboembolic event is approximately $4000 - $5550, while the annual cost of treating one case of VTE is betwe
Read Article


